PAVmed Inc. (PAVM)
Market Cap | 11.25M |
Revenue (ttm) | 1.99M |
Net Income (ttm) | 72.45M |
Shares Out | 17.62M |
EPS (ttm) | 0.96 |
PE Ratio | 0.67 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 156,264 |
Open | 0.6780 |
Previous Close | 0.6784 |
Day's Range | 0.6352 - 0.6780 |
52-Week Range | 0.5500 - 1.9000 |
Beta | 1.06 |
Analysts | Strong Buy |
Price Target | 19.00 (+2,875.72%) |
Earnings Date | Aug 11, 2025 |
About PAVM
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PAVM stock is "Strong Buy" and the 12-month stock price forecast is $19.0.
News

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAVmed ...

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed I...

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive ...

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of ...

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in pro...

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical techno...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention m...

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Co...

Lucid Diagnostics Announces Closing of Public Offering of Common Stock
NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Lucid Diagnostics Announces Proposed Public Offering of Common Stock
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics I...

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Confe...

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris Health secured financing to resume advance...

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concier...

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswi...

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnosti...

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or ...

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me...

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
NEW YORK , March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
NEW YORK , March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed...

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD...

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed ...

PAVmed and Subsidiary Veris Health Complete Private Placement Financing
Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire...